Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and Europe, where semaglutide is also sold as Wegovy for weight loss, India has approved Ozempic only for type-2 diabetes management.

Ozempic, a GLP-1 receptor agonist, has officially launched in India, offering a new treatment option for type 2 diabetes. While known for its weight loss benefits, its approved use in India is solely for diabetes management,

Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here’s a quick look at what this popular diabetes drug really means for Indian

Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting cosmetic concerns while noting they are not serious health risks.

A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked online debate. While proponents highlight its benefits for heart health, metabolism,

Researchers have created an oral medication that could work alone or with GLP-1 drugs to improve metabolic health while preserving muscle mass in diabetes patients.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines will be needed in India where obesity is a growing concern. For the moment, expect interest and action as the weight-loss war hots up in the days and months ahead.

GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, reshaping how doctors and patients think about obesity. As prescriptions climb,